U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Fallopian Tube Undifferentiated Carcinoma

MedGen UID:
1791618
•Concept ID:
C5555177
•
Neoplastic Process

Definition

Fallopian tube undifferentiated carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Fallopian Tube Undifferentiated Carcinoma

Professional guidelines

PubMed

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623
SOGC clinical guidelines. Hysterectomy.
Lefebvre G, Allaire C, Jeffrey J, Vilos G, Arneja J, Birch C, Fortier M; Clinical Practice Gynaecology Committee and Executive Committeee and Council, Society of Obstetricians and Gynaecologists of Canada
J Obstet Gynaecol Can 2002 Jan;24(1):37-61; quiz 74-6. PMID: 12196887

Recent clinical studies

Etiology

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol 2023 Jul;19(23):1577-1591. Epub 2023 Jun 19 doi: 10.2217/fon-2023-0246. PMID: 37334673
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252

Diagnosis

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Spontaneous resolution of dermatomyositis associated with fallopian-tube carcinoma following staging surgery: A case report.
Lin C, Ying Z, Sijing C
Medicine (Baltimore) 2019 Mar;98(10):e14530. doi: 10.1097/MD.0000000000014530. PMID: 30855437Free PMC Article
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW
Gynecol Oncol 2015 Aug;138(2):272-7. Epub 2015 May 27 doi: 10.1016/j.ygyno.2015.05.023. PMID: 26026738
Resection of recurrent ovarian or fallopian tube carcinoma involving the liver.
Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS
Gynecol Oncol 2003 Nov;91(2):383-8. doi: 10.1016/j.ygyno.2003.07.005. PMID: 14599870
A case of uterine endometrial carcinoma 15 months post-partum.
Ishioka S, Sagae S, Saito T, Sugimura M, Akutagawa N, Nishimura M, Ezaka Y, Kudo R
J Obstet Gynaecol Res 2000 Dec;26(6):417-20. doi: 10.1111/j.1447-0756.2000.tb01351.x. PMID: 11152326

Therapy

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D
J Clin Oncol 2023 Oct 20;41(30):4779-4789. Epub 2023 Jun 26 doi: 10.1200/JCO.22.02624. PMID: 37364223Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA
J Obstet Gynaecol 2022 Aug;42(6):2331-2335. Epub 2022 Apr 26 doi: 10.1080/01443615.2022.2049724. PMID: 35470751
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
Cisternino A, Capone L, Rosati A, Latiano C, Sebastio N, Colella A, Cretì G
Arch Ital Urol Androl 2023 May 22;95(2):11058. doi: 10.4081/aiua.2023.11058. PMID: 37212881
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...